Latest News about TAK
Recent news which mentions TAK
Seagen's Adcetris/Immunotherapy Combo Achieves 98% Overall Response Rate in Early-Stage Lymphoma Setting
June 13, 2023
From Benzinga
3 Stocks That Could Skyrocket by This Time Next Summer
June 08, 2023
From InvestorPlace
Why Shares of Innate Pharma Jumped Thursday
June 08, 2023
From Motley Fool
FDA Approves First Oral Treatment For Crohn's Disease, Making Seventh Approval For AbbVie's Rinvoq
May 19, 2023
From Benzinga
From Benzinga
Earnings Scheduled For May 11, 2023
May 11, 2023
From Benzinga
From Benzinga
Cannabis Movers & Shakers: Latest Appointments From Khiron, MariMed, Equilibria & More
April 25, 2023
From Benzinga
Why Shares of Arrowhead Pharmaceuticals Are Up Tuesday
April 25, 2023
From Motley Fool
From Motley Fool
United Nations' Specialized Agency In Preliminary Talks With Takeda For Dengue Vaccine, Currently Under FDA Review
April 21, 2023
From Benzinga
From InvestorPlace
From Benzinga
Takeda's Highest Dose Psoriasis Candidate Can Potentially Beat Bristol Myers' Approved Drug, Analyst Says
March 20, 2023
From Benzinga
From Benzinga
From Benzinga
Should You Give Up on Novavax?
March 03, 2023
From Motley Fool
2 Incredibly Cheap High-Yield Dividend Stocks to Buy Now
February 28, 2023
From Motley Fool
Takeda Presents Vedolizumab Data For Preventing Graft-Versus-Host Disease In Stem Cell Transplant Patients
February 21, 2023
From Benzinga
Is This the Telltale Sign to Sell Novavax Stock?
February 14, 2023
From Motley Fool
Takeda Reports 13% Fall In Nine Month Operating Profit, Keeps Annual Guidance Unchanged
February 02, 2023
From Benzinga
7 Sorry Dividend Stocks to Sell in February Before It’s Too Late
January 30, 2023
From InvestorPlace
Finch Therapeutics Halts Work On Its Only Clinical Stage Asset, Cuts 95% Of Workforce
January 24, 2023
From Benzinga
HUTCHMED Out Licenses Fruquintinib To Takeda Outside China
January 23, 2023
From Benzinga
From Benzinga
From Benzinga
Takeda To Add Mid-Stage Autoimmune Disease Candidate For $4B
December 13, 2022
From Benzinga
Exelixis' Cabometyx/Tecentriq Combo Misses Overall Survival Goal In Lung Cancer Setting
December 09, 2022
From Benzinga
From Motley Fool
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.